Artiva Biotherapeutics (NASDAQ:ARTV) Insider Christopher Horan Sells 7,002 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Christopher Horan sold 7,002 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total value of $63,088.02. Following the completion of the sale, the insider directly owned 293,450 shares in the company, valued at $2,643,984.50. This represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ:ARTV opened at $8.55 on Wednesday. The business’s 50 day moving average price is $8.32 and its 200-day moving average price is $5.65. The firm has a market capitalization of $211.36 million, a PE ratio of -2.42 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter valued at $41,000. Bank of America Corp DE raised its position in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the period. Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the second quarter valued at $53,000. Qube Research & Technologies Ltd purchased a new stake in Artiva Biotherapeutics in the second quarter valued at $58,000. Finally, Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the second quarter valued at $67,000.

Wall Street Analyst Weigh In

ARTV has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Cantor Fitzgerald lifted their price objective on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. HC Wainwright lifted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.